Literature DB >> 25076704

Possible progression of subacute lupus erythematosus--case report.

Daciana Elena Brănişteanu, Andreea Lăbonţu, Delia Ciobanu, Gabriela Stoleriu, D Brănişteanu, A Oanţă.   

Abstract

Subacute lupus erythematosus (SLE) is a specific form of lupus erythematosus characterized by prevalently cutaneous manifestations usually with a good prognosis. It is more common in patients aged 15 to 70 years, and there is a female predilection. This form accounts for 10% of all lupus erythematosus cases. We present the case of a 57-year-old male patient diagnosed at age 35 with chronic psoriasiform subacute lupus erythematosus, pathologically confirmed at the Iaşi Dermatology Clinic. At the age of 54 years he had multiple ischemic strokes, followed by deterioration of general status, and at 56 years deep vein thrombosis in the right leg. The patient presented the erythematous-squamous lesions specific to psoriasiform SLE localized both on the upper third of the body and knees and associated with submucosal lesions of the lower lip, oral mucosa and appendages. The patient also presented hypo- and hyperpigmentated atrophic scar-like lesions. Laboratory tests performed during the last two admissions showed the presence of anti-ds DNA and antiphospholipid antibodies, inflammatory syndrome, and nitrogen retention syndrome. Treatment consisted of systemic and local dermatocorticoids and associated medication, emollient lotions and creams with SPF 50+, with slowly favorable progression. The peculiarity of the case lies in the chronic progression without significant systemic involvement for 19 years, and then in 2 years the antiphospholipid antibody syndrome and a shift to systemic lupus erythematosus to occur.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25076704

Source DB:  PubMed          Journal:  Rev Med Chir Soc Med Nat Iasi        ISSN: 0048-7848


  1 in total

1.  Drug-induced Rowell syndrome, a rare and difficult to manage disease: A case report.

Authors:  Daciana Elena Brănișteanu; Simona Laura Ianoşi; Andreea Dimitriu; Gabriela Stoleriu; Alexandru Oanţǎ; Daniel Constantin Brănișteanu
Journal:  Exp Ther Med       Date:  2017-11-23       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.